Clinical Trial Update: S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial S0331 evaluated imatinib mesylate in patients with metastatic or unresectable Merkel cell carcinoma. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin | Phase 2 | Status: COMPLETED